Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173169 · ClinicalTrials.gov registry record · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT04173169 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 103 participants.
The verdict
NCT04173169, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Interventions
- DRUG Elagolix 200 MG
- OTHER Placebo or SOC IVF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2025-05-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04173169
The ClinicalTrials.gov registry entry for NCT04173169 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Elagolix 200 MG is the first listed.
NCT04173169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04173169 about?
NCT04173169 is a clinical study titled "Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis". A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET...
What is the current status of trial NCT04173169?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2022-03-15. Estimated completion is 2025-05-02.
What interventions are being tested in trial NCT04173169?
The interventions under investigation include: Elagolix 200 MG (DRUG), Placebo or SOC IVF (OTHER).
Who is sponsoring clinical trial NCT04173169?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.